Nanoplasmonic Biosensor Detecting Autophagy Markers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting autophagy markers, such as Western blotting and ELISA, are limited in sensitivity and accuracy, particularly in quantifying individual LC3 forms, which is crucial for cancer therapy drug screening and clinical applications where sample concentrations are low.
Innovation Solution
A nanoplasmonic biosensor using immunogold nanorods linked with monoclonal antibodies specifically binding to autophagy markers, measuring localized surface plasmon resonance to detect LC3-I and LC3-II with high sensitivity across a wide concentration range, enabling label-free detection and accurate quantification of autophagic flux.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If Western blotting or ELISA is used to detect autophagy markers, then the detection can be performed with conventional methods, but the sensitivity and accuracy are insufficient particularly in quantifying individual LC3 forms
Solution Approach 1:
The patent replaces conventional mechanical/chemical detection methods (Western blotting, ELISA) with a plasmonic optical detection system. Gold nanorods exhibit localized surface plasmon resonance (LSPR) that shifts in response to binding events, enabling label-free, real-time detection with femtomolar sensitivity. This optical field-based detection substitutes the mechanical separation and chemical reaction steps of traditional methods.
Solution Approach 2:
The patent changes the detection parameter from bulk optical signals in ELISA to localized surface plasmon resonance wavelength shifts in gold nanorods. The LSPR peak wavelength is highly sensitive to the local refractive index changes caused by molecular binding, enabling detection at femtomolar concentrations with high precision while maintaining operational simplicity.
2Measurement precision
If conventional LC3 assays are used, then total LC3 quantification can be achieved, but it is impossible to quantify individual LC3 forms (LC3-I and LC3-II)
Solution Approach 1:
The patent segments the detection of total LC3 into separate detections of LC3-I and LC3-II by using two distinct antibody pairs with different affinities. The first antibody pair binds both forms, while the second antibody pair specifically distinguishes between them through differential binding kinetics. This segmentation enables individual quantification without requiring complex gel electrophoresis separation.
Solution Approach 2:
The patent employs a two-step detection protocol with feedback from the first measurement to guide the second. The initial binding equilibrium is established, then a second antibody is introduced that differentially binds LC3-I and LC3-II. The system uses the feedback from the first binding event to calculate the individual concentrations through mathematical modeling of the binding equilibria, enabling accurate quantification of each form.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The biosensor achieves 20-fold higher sensitivity than conventional ELISA, accurately quantifying LC3 forms in femtomolar to nanomolar concentrations, facilitating rapid and reliable drug screening and clinical applications by determining autophagic flux and cancer therapeutic agent efficacy.
Implementation Method 1
measuring localized surface plasmon resonance in the immunogold nanorods
Implementation Method 2
immunogold nanorods immobilized on the substrate and linked with a monoclonal antibody specifically binding to an autophagy marker
Data Source
AI summary
Disclosed are a nanoplasmonic biosensor for detecting an autophagy marker with high sensitivity using a plasmon resonance effect, and a method of detecting an autophagy marker and a method of screening a cancer therapeutic agent using the same.